Fexofenadine Tablets

Contract SPE2D2-25-D-0005 is an award issued by the Defense Logistics Agency DLA Troop Support to Radha Pharmaceuticals Inc. for the procurement of Fexofenadine tablets in various dosages and counts. The total potential award value is 10,819,189.25 dollars, covering a base year and four option years. The contract includes the supply of 60MG tablets in 100 and 500 count bottles, and 180MG tablets in 30, 100, and 500 count bottles. Performance is based on FOB Destination terms, with primary compounding and production occurring at the ScieGen Pharmaceuticals Inc. facility in Hauppauge, New York. Modification P00003 executed Option 1 of the contract for the period of February 18, 2026, to February 17, 2027. The agreement is subject to various federal regulations, including strict cybersecurity standards under NIST SP 800-171 and reporting requirements for executive compensation and critical mineral sourcing. The acquisition was set aside for multiple socioeconomic categories, including Small Business, HUBZone, SDVOSB, WOSB, and EDWOSB. Administration is managed by the DLA office in Philadelphia, Pennsylvania, with electronic invoicing mandated for all payments.